You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 13, 2024

CLINICAL TRIALS PROFILE FOR INTUNIV


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for INTUNIV

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00734578 ↗ Efficacy and Safety of SPD503 in Combination With Psychostimulants Completed Shire Phase 3 2008-09-02 The purpose of this study is to assess the efficacy and safety of SPD503 in subjects with ADHD when co-administered with psychostimulants in children and adolescents aged 6-17 years with a diagnosis of ADHD with a sub-optimal, partial response to stimulants.
NCT00901576 ↗ A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers Completed Shire Phase 1 2009-05-18 This is a drug-drug interaction study; the purpose of this study is to examine the pharmacokinetics (levels of drug in the blood) of SPD503 (guanfacine hydrochloride) and Concerta (methylphenidate HCl) when given alone, and in combination.
NCT00997984 ↗ Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study) Completed Shire Phase 3 2009-11-17 The primary purpose is to assess the efficacy of once daily dosing with optimized SPD503 (1, 2, 3 and 4mg/day), dosed either in the morning or evening, compared to placebo, in children with ADHD as measured by change from baseline score at endpoint on the ADHD-RS-IV.
NCT01069523 ↗ Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD) Completed Shire Phase 4 2010-03-01 All subjects with the study will be children (age 6-12) with Attention Deficit Hyperactivity Disorder (ADHD). After baseline assessment confirms the presence of ADHD, children will have an Event related potential (ERP) (a type of electroencephalogram [EEG]) study. After the baseline EEG, children will be randomized to either placebo or GXR for a 4-week, parallel groups trial. During this trial, dosing will be flexibly adjusted according to patient response or presence of side effects. The dosage will range from 1-4 mg. At the end of the four week trial, a follow up ERP study will be obtained.
NCT01069523 ↗ Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD) Completed The University of Texas Health Science Center at San Antonio Phase 4 2010-03-01 All subjects with the study will be children (age 6-12) with Attention Deficit Hyperactivity Disorder (ADHD). After baseline assessment confirms the presence of ADHD, children will have an Event related potential (ERP) (a type of electroencephalogram [EEG]) study. After the baseline EEG, children will be randomized to either placebo or GXR for a 4-week, parallel groups trial. During this trial, dosing will be flexibly adjusted according to patient response or presence of side effects. The dosage will range from 1-4 mg. At the end of the four week trial, a follow up ERP study will be obtained.
NCT01081132 ↗ Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl Completed Shire Phase 3 2011-09-19 To assess the efficacy of optimized Extended-release Guanfacine Hydrochloride compared with placebo in the treatment of adolescents aged 13-17 years with a diagnosis of ADHD as measured by the ADHD-RS-IV
NCT01133847 ↗ Interventions for Children With Attention and Reading Disorders Completed Children's Hospital Medical Center, Cincinnati Phase 4 2010-11-01 The objective of this randomized clinical trial is to address unanswered questions about the relative effectiveness of treatments for children with both Attention Deficit Hyperactivity Disorder (ADHD) and significant reading difficulties (RD). The study evaluates attentional and word reading outcomes for students with both conditions when provided with either (a) ADHD treatment alone, (b) RD treatment alone, or (c) the combination of ADHD and RD treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for INTUNIV

Condition Name

Condition Name for INTUNIV
Intervention Trials
Attention Deficit Hyperactivity Disorder 7
ADHD 3
Attention Deficit Hyperactivity Disorder (ADHD) 3
Attention-deficit/Hyperactivity Disorder 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for INTUNIV
Intervention Trials
Attention Deficit Disorder with Hyperactivity 17
Hyperkinesis 13
Disease 12
Aggression 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for INTUNIV

Trials by Country

Trials by Country for INTUNIV
Location Trials
United States 145
United Kingdom 8
Spain 7
Canada 6
Poland 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for INTUNIV
Location Trials
New York 9
Texas 8
Connecticut 8
Florida 7
California 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for INTUNIV

Clinical Trial Phase

Clinical Trial Phase for INTUNIV
Clinical Trial Phase Trials
Phase 4 14
Phase 3 5
Phase 2 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for INTUNIV
Clinical Trial Phase Trials
Completed 20
Recruiting 4
Active, not recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for INTUNIV

Sponsor Name

Sponsor Name for INTUNIV
Sponsor Trials
Shire 16
Yale University 7
National Institute on Drug Abuse (NIDA) 4
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for INTUNIV
Sponsor Trials
Other 34
Industry 17
NIH 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.